If you purchased shares of GenVec, Inc. (NASDAQ: GNVC), you may have certain options and you should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of GenVec, Inc. (NASDAQ:GNVC)
On March 29, 2010, GenVec, Inc. (Nasdaq: GNVC) announced that it is discontinuing its Phase 3 clinical trial of TNFerade(TM)
GenVec said that it has determined, after conferring with its independent Data Safety Monitoring Board, that the PACT trial would not meet the goal of demonstrating persuasive evidence of clinical effectiveness that could form the basis for regulatory approval in the population chosen for study.
For more information go to www.ShareholdersFoundation.com or contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
# # #
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Photo:
http://www.prlog.org/




